InvestorsHub Logo
icon url

ku

05/19/16 8:52 PM

#264474 RE: biopharm #264472

Bipharm,

Magical because according to your research it cures all the human, animal and plant diseases

KU, you and some others are really getting each bloomers in a twist and excited over nothing that has happened... YET

All I am saying is that nobody seems to know the status of one study and one abstract and that is because of management's lack of communication and lack of respect for shareholders that are down thousands of dollars.

Keep it simple and realize that all the puzzle pieces point to big things in the works and NCCN, MSK and AstraZeneca are excited for the right reasons

I do not want to go thru a second Reverse Split while all the entities that you mentioned above (The System) decides what to do with Bavi and WHEN to do it while the management and BOD hang out and collect massive salaries.

That's all I am saying buddy
icon url

senrex

05/20/16 7:09 AM

#264484 RE: biopharm #264472

that is all you need to say.... but its not really magical. Flipped PS was just never targeted in a way that the late Dr. Phil Thorpe has discovered



Biopharm: but isn't this the issue: Flipped PS is one thing. But we have no evidence that Bavi accomplishes this in humans. SUNRISE was either a failure (thus the end of the trial); OR the trial was simply designed poorly. I will not go down the sabotaged control arm again: I'm beginning to get so paranoid I keep thinking people are following me.

Now, after Phase ll fiasco and SUNRISE, we're supposed to throw 16 years of hope (in my case) into the I-O scenario -- despite having zero success in any previous trial. I just do not understand why this is not more unsettling to the optimists on the Board.

People are rightfully outraged that with a pending RS (which means that someone with 20k shares sees them reduced to 2000 and then watch the shorts who have always controlled this security drop the share orice to a point where the monetary value us cut to 5% of your original investment) this management remains persistently contemptuous of retail investors.